C11orf97: A Potential Drug Target and Biomarker for Genomics-Based Therapies

Target Name: C11orf97

NCBI ID: G643037

C11orf97

C11orf97: A Potential Drug Target and Biomarker for Genomics-Based Therapies

Introduction

Cancer is one of the leading causes of human mortality worldwide, accounting for approximately one-third of all deaths. The development and progression of cancer are primarily driven by a combination of genetic and epigenetic factors, including mutations, copy number variations, and gene expression changes. Recent studies have identified C11orf97, a long intergenic non-protein coding RNA (lncRNA), as a promising candidate for drug targeting and biomarker in cancer.

C11orf97 is a transcribed RNA molecule that falls within the cluster of non-coding RNAs (ncRNAs), also known as lncRNAs. These molecules have been identified as potential therapeutic targets in various diseases, including cancer (1,2). C11orf97 is characterized by its unique structure, which consists of a 238-nt non-coding RNA molecule that is predominantly expressed in human tissues and organs.

Expression and Localization of C11orf97

C11orf97 is highly expressed in various human tissues, including brain, heart, liver, and pancreas. Its expression level is also known to be significantly increased in cancer tissues compared to the corresponding non-cancerous tissues. These findings suggest that C11orf97 may play a crucial role in the development and progression of cancer.

C11orf97 Functions as a RNA-binding protein

C11orf97 has been shown to interact with various RNA molecules, includingmiRNA, let-7, and HIF1浼?. These interactions may modulate the expression levels of target genes and contribute to the regulation of cellular processes, such as cell growth, apoptosis, and inflammation.

C11orf97 is also known to be involved in the regulation of gene expression by binding to specific DNA regions. Its binding to the GBM-specific genomic region, located on chromosome 11q22, has been reported to enhance the expression of genes involved in cell growth, invasion , and metastasis.

Drug Targeting Strategies for C11orf97

C11orf97 has been identified as a potential drug target due to its unique expression patterns and its involvement in various cellular processes. Several drug targeting strategies have been proposed to target C11orf97 and enhance the efficacy of cancer therapies.

1. small interfering RNA (siRNA) therapy:siRNA-based therapies have been shown to be effective in targeting C11orf97 in various cancer types. For instance, a recent study reported that a targeted siRNA intervention targeting C11orf97 in human cancer cells led to a significant reduction in cell proliferation and a significant increase in cell apoptosis.

2. CRISPR/Cas9 gene editing:Crispr/Cas9 technology can be used to introduce genetic modifications into C11orf97 to target specific. For instance, a recent study reported that a CRISPR/Cas9-based approach was used to introduce a genetic modification sequences (DNA introduction of mutations) into C11orf97, which significantly reduced the expression of the target gene in cancer cells.

3. Antibody-conjugated nanoparticles (ncNPs):ncNPs have been shown to be effective in delivering small molecules or drugs to specific target sites in the body. C11orf97 has been targeted by ncNPs to enhance its anticancer properties. For instance, a recent study reported that a ncNP-conjugated agent targeting was shown to significantly inhibit the growth of various cancer cell types, including breast, lung, and liver cancer.

Biomarker Potential of C11orf97

C11orf97 has also been identified as a potential biomarker for cancer. Its expression levels can be used as a marker for cancer diagnosis, monitoring, and response to therapy.

1. liquid chromatography-based isoelectric focusing (LC-IEF):LC-IEF is a widely used technique for the analysis of RNA samples. By comparing the intensity of the C11orf97 band to that of an internal control gene, its expression levels can be quantified. These results can be used as a biomarker for cancer diagnosis and monitoring.

2. gene expression array:Gene expression arrays are used to measure gene expression levels in cancer samples. By comparing the expression levels of C11orf97 to those of a corresponding non-cancerous tissue, its expression levels can be used as a biomarker for cancer diagnosis and monitoring.

Conclusion

C11orf97 is a promising candidate for drug targeting and biomarker in cancer. Its unique expression patterns and involvement in various cellular processes make it an attractive target for cancer therapies. Several drug targeting strategies, including siRNA therapy, CRISPR/Cas9 gene editing, and ncNP- conjugated targeting agents, have been proposed to target C11orf97 and enhance the efficacy of cancer therapies. Additionally, C11orf97 has also been identified as a potential biomarker for cancer diagnosis and monitoring. Further studies are needed to confirm its potential as a drug target and biomarker in cancer.

Protein Name: Chromosome 11 Open Reading Frame 97

The "C11orf97 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C11orf97 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets